Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,678.42
(
-0.56%
)
US TECH 100
24,034.40
(
-0.41%
)
Dow Jones
46,572.79
(
-0.89%
)
Brent Oil
105.81
(
5.13%
)
Bitcoin
71,353.35
(
-3.50%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 79035

Thursday, 06/04/2009 5:50:18 PM

Thursday, June 04, 2009 5:50:18 PM

Post# of 257253
Strike Three for TLR’s in HCV!

Can investors now conclude that TLR’s are not the way to go in treating HCV? Let’s recap the progress to date:

• Jan 2007: Coley Pharmaceuticals drops Actilon, a TLR9 agonist that did not have much efficacy (#msg-16403804). Strike one.

• Jul 2007: ANDS discontinues ANA975, a TLR7 agonist that showed unacceptable liver toxicity (#msg-21600252). Strike two.

• Today: ANDS cans ANA773, a TLR7 agonist that’s the son of ANA975 (#msg-38418158). Strike three—you’re out!

If anyone thinks TLR’s still have a place in the treatment of HCV, speak now or forever hold your peace!


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now